ALA/ALC

ALA – ALC 60 capsules

$27.97

Out of stock

Want a discount? Become a member by purchasing Wellness Club Membership!
SKU: N331 Category:

Description

Alpha Lipoic Acid / Acetyl L-Carnitine

Two Energy Powerhouses in One High-Potency Formula

Alpha lipoic acid and acetyl L-carnitine are two “powerhouses” for energy production.

Alpha Lipoic acid improves mitochondrial function (the “energy producing units” of the cell) is also involved in the conversion of carbohydrates to energy. It is used for:

  • overweight and obesity
  • brain health
  • neurological disease
  • cataract prevention
  • diabetes
  • heart disease
  • detoxification support

Acetyl-L-Carnitine (ALC), a derivative of the amino acid L-carnitine, is a vitamin-like compound that transports fatty acids (“fuel”) into cells.  It has been approved in Europe as a “drug” to treat heart and neurological disease. It also acts as a powerful antioxidant in the brain.  The acetyl form of L-carnitine (ALC) was found to be substantially more active than L-carnitine in brain cells.

Together, these two nutrients pack a powerful punch.

For example, the combination of ALA and ALC was found, when fed to old rats, to significantly improve metabolic function while decreasing oxidative stress and improving cognition (thought function) suggesting it’s value in an Anti Aging program. According to the researchers:

“Supplementing the diet of old rats with ALCAR+LA [ALA / ALC] significantly improves many of the most frequently encountered age-related changes in mammals — namely loss of energy metabolism, increased oxidative stress, decreased physical activity, and […] impaired cognitive function.” (48)

The combination also proved valuable in patients with coronary artery disease and hypertension, and metabolic syndrome:

” Alpha-lipoic acid and acetyl-L-carnitine reduce oxidative stress and improve mitochondrial function. […] we examined the effects of combined alpha-lipoic acid /acetyl-L-carnitine treatment and placebo (eight weeks per treatment) on vasodilator function and blood pressure in 36 subjects with coronary artery disease. Active treatment increased brachial artery diameter by 2.3%, consistent with reduced arterial tone. Active treatment tended to decrease systolic blood pressure for the whole group and had a significantly effect in the subgroup with blood pressure above the median and in the subgroup with the metabolic syndrome…” (57)

In addition to individual formulas of ALA and ALC, we now offer a high-potency supplement which combines both nutrients in a single formula.

One bottle of ALA-ALC is equivalent to two bottles each of our separate ALA and ALC formulas. For those who need to take both nutrients in higher potencies, this represents a savings of over $30.

Supplemental Facts

Serving Size: 1 Capsule(s)
Acetyl L-Carnitine 525 mg
Alpha Lipoic Acid 225 mg

Other Ingredients: Gelatin, magnesium stearate, and stearic acid.

Recommended Dose: One or two caps daily or as directed by your healthcare professional.

ALA-ALC 60 capsules $27.97

References:

  1. Noland RC, Koves TR, Seiler SE, Lum H, Lust RM, Ilkayeva O, Stevens RD, Hegardt FG, Muoio DM. Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem. 2009 Aug 21;284(34):22840-52. Epub 2009 Jun 24.
  2. Pescosolido N, Imperatrice B, Karavitis P. Ocular disorders secondary to systemic disease and the potential role of carnitines. Drugs R D. 2008;9 Suppl 1:15-22. doi: 10.2165/0126839-200809001-00003.
  3. Power RA, Hulver MW, Zhang JY, Dubois J, Marchand RM, Ilkayeva O, Muoio DM, Mynatt RL.Carnitine revisited: potential use as adjunctive treatment in diabetes. Diabetologia. 2007 Apr;50(4):824-32. Epub 2007 Feb 20.
  4. Siliprandi N, Siliprandi D, Ciman M. Stimulation of oxidation of mitochondrial fatty acids and of acetate by acetylcarnitine. Biochem J. 1965 Sep;96(3):777-80.
  5. Stephens FB, Constantin-Teodosiu D, Greenhaff PL. New insights concerning the role of carnitine in the regulation of fuel metabolism in skeletal muscle. J Physiol. 2007 Jun 1;581(Pt 2):431-44. Epub 2007 Mar 1.
  6. Calvani M, Reda E, Arrigoni-Martelli E. Regulation by carnitine of myocardial fatty acid and carbohydrate metabolism under normal and pathological conditions. Basic Res Cardiol. 2000 Apr;95(2):75-83.
  7. Ferrari R, Merli E, Cicchitelli G, Mele D, Fucili A, Ceconi C. Therapeutic effects of L-carnitine and propionyl-L-carnitine on cardiovascular diseases: a review. Ann N Y Acad Sci. 2004 Nov;1033:79-91.
  8. Iliceto S, Scrutinio D, Bruzzi P, D’Ambrosio G, Boni L, Di Biase M, Biasco G, Hugenholtz PG, Rizzon P. Effects of L-carnitine administration on left ventricular remodeling after acute anterior myocardial infarction: the L-Carnitine Ecocardiografia Digitalizzata Infarto Miocardico (CEDIM) Trial.J Am Coll Cardiol. 1995 Aug;26(2):380-7.
  9. Lango R, Smolenski RT, Narkiewicz M, Suchorzewska J, Lysiak-Szydlowska W. Influence of L-carnitine and its derivatives on myocardial metabolism and function in ischemic heart disease and during cardiopulmonary bypass. Cardiovasc Res. 2001 Jul;51(1):21-9.
  10. Siliprandi N, Di Lisa F, Pivetta A, Miotto G, Siliprandi D.Transport and function of L-carnitine and L-propionylcarnitine: relevance to some cardiomyopathies and cardiac ischemia. Z Kardiol. 1987;76 Suppl 5:34-40.
  11. Calabrese V, Cornelius C, Mancuso C, Lentile R, Stella AM, Butterfield DA. Redox homeostasis and cellular stress response in aging and neurodegeneration. Methods Mol Biol. 2010;610:285-308.
  12. Carta A, Calvani M. Acetyl-L-carnitine: a drug able to slow the progress of Alzheimer’s disease? Ann N Y Acad Sci. 1991;640:228-32.
  13. Carta A, Calvani M, Bravi D, Bhuachalla SN. Acetyl-L-carnitine and Alzheimer’s disease: pharmacological considerations beyond the cholinergic sphere. Ann N Y Acad Sci. 1993 Sep 24;695:324-6.
  14. Epis R, Marcello E, Gardoni F, Longhi A, Calvani M, Iannuccelli M, Cattabeni F, Canonico PL, Di Luca M. Modulatory effect of acetyl-L-carnitine on amyloid precursor protein metabolism in hippocampal neurons. Eur J Pharmacol. 2008 Nov 12;597(1-3):51-6. Epub 2008 Sep 6.
  15. Liu J.The effects and mechanisms of mitochondrial nutrient alpha-lipoic acid on improving age-associated mitochondrial and cognitive dysfunction: an overview. Neurochem Res. 2008 Jan;33(1):194-203. Epub 2007 Jun 29
  16. Bianchi G, Vitali G, Caraceni A, Ravaglia S, Capri G, Cundari S, Zanna C, Gianni L. Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer. 2005 Aug;41(12):1746-50.
  17. Chiechio S, Copani A, Gereau RW 4th, Nicoletti F. Acetyl-L-carnitine in neuropathic pain: experimental data. CNS Drugs. 2007;21 Suppl 1:31-8; discussion 45-6.
  18. De Grandis D. Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review. CNS Drugs. 2007;21 Suppl 1:39-43; discussion 45-6.
  19. Ghirardi O, Vertechy M, Vesci L, Canta A, Nicolini G, Galbiati S, Ciogli C, Quattrini G, Pisano C, Cundari S, Rigamonti LM. Chemotherapy-induced allodinia: neuroprotective effect of acetyl-L-carnitine. In Vivo. 2005 May-Jun;19(3):631-7.
  20. Hart AM, Wilson AD, Montovani C, Smith C, Johnson M, Terenghi G, Youle M. Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy. AIDS. 2004 Jul 23;18(11):1549-60.
  21. Herzmann C, Johnson MA, Youle M. ng-term effect of acetyl-L-carnitine for antiretroviral toxic neuropathy. HIV Clin Trials. 2005 Nov-Dec;6(6):344-50.
  22. Osio M, Muscia F, Zampini L, Nascimbene C, Mailland E, Cargnel A, Mariani C. Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study. J Peripher Nerv Syst. 2006 Mar;11(1):72-6.
  23. Pisano C, Pratesi G, Laccabue D, Zunino F, Lo Giudice P, Bellucci A, Pacifici L, Camerini B, Vesci L, Castorina M, Cicuzza S, Tredici G, Marmiroli P, Nicolini G, Galbiati S, Calvani M, Carminati P, Cavaletti G. Paclitaxel and Cisplatin-induced neurotoxicity: a protective role of acetyl-L-carnitine. Clin Cancer Res. 2003 Nov 15;9(15):5756-67.
  24. Youle M. Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.CNS Drugs. 2007;21 Suppl 1:25-30; discussion 45-6.
  25. Malaguarnera M, Gargante MP, Cristaldi E, Vacante M, Risino C, Cammalleri L, Pennisi G, Rampello L. Acetyl-L-carnitine treatment in minimal hepatic encephalopathy.Dig Dis Sci. 2008 Nov;53(11):3018-25. Epub 2008 Mar 21.
  26. Malaguarnera M, Pistone G, Astuto M, Vecchio I, Raffaele R, Lo Giudice E, Rampello L. Effects of L-acetylcarnitine on cirrhotic patients with hepatic coma: randomized double-blind, placebo-controlled trial. Dig Dis Sci. 2006 Dec;51(12):2242-7. Epub 2006 Nov 1
  27. Mingrone G.Carnitine in type 2 diabetes. Ann N Y Acad Sci. 2004 Nov;1033:99-107.
  28. Rosca MG, Lemieux H, Hoppel CL. Mitochondria in the elderly: Is acetylcarnitine a rejuvenator? Adv Drug Deliv Rev. 2009 Nov 30;61(14):1332-42. Epub 2009 Aug
  29. Calabrese V, Giuffrida Stella AM, Calvani M, Butterfield DA.Acetylcarnitine and cellular stress response: roles in nutritional redox homeostasis and regulation of longevity genes. J Nutr Biochem. 2006 Feb;17(2):73-88. Epub 2005 Oct 18.
  30. Liu J, Killilea DW, Ames BN. Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L- carnitine and/or R-alpha -lipoic acid.Proc Natl Acad Sci U S A. 2002 Feb 19;99(4):1876-81.
  31. Packer L, Tritschler HJ, Wessel K. Neuroprotection by the metabolic antioxidant alpha-lipoic acid. Free Radic Biol Med 1997;22(1-2):359-78.
  32. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040–3.
  33. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040–3.
  34. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171–9.
  35. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296–301.
  36. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–83.
  37. Konrad T, Vicini P, Kusterer K, et al. alpha lipoic acid treatment decreases serum lactate and pyruvate concentrations and improves glucose effectiveness in lean and obese patients with type 2 diabetes. Diabetes Care 1999;22:280–7.
  38. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040–3.
  39. Ruhnau KJ, Meissner HP, Finn JR, et al. Effects of 3-week oral treatment with the antioxidant thioctic acid (alpha-lipoic acid) in symptomatic diabetic polyneuropathy. Diabet Med 1999;16:1040–3.
  40. Reljanovic M, Reichel G, Rett K, et al. Treatment of diabetic polyneuropathy with the antioxidant thioctic acid (alpha-lipoic acid): a two year multicenter randomized double-blind placebo-controlled trial (ALADIN II). Alpha Lipoic Acid in Diabetic Neuropathy. Free Radic Res 1999;31:171–9.
  41. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Diabetes Care 1997;20:369–73.
  42. Jacob S, Ruus P, Hermann R, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: a placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309–14.
  43. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296–301.
  44. Ziegler D, Ametov A, Barinov A, et al. Oral treatment with alpha-lipoic acid improves symptomatic diabetic polyneuropathy: the SYDNEY 2 trial. Diabetes Care 2006;29:2365–70.
  45. Morcos M, Borcea V, Isermann B, et al. Effect of alpha-lipoic acid on the progression of endothelial cell damage and albuminuria in patients with diabetes mellitus: an exploratory study. Diabetes Res Clin Pract 2001;52:175–83.
  46. L. Packer, E.H.Witt, H.J. Tritschler, Free Rad Biol and Med 1995; 19: 227-250.
    47.) Liu J, Atamna H, Kuratsune H, Ames BN. Delaying brain mitochondrial decay and aging with mitochondrial antioxidants and metabolites. Ann N Y Acad Sci 2002 Apr;959:133-66.
  47. Liu J, Head E, Gharib AM, Yuan W, Ingersoll RT, Hagen TM, Cotman CW, Ames BN. Memory loss in old rats is associated with brain mitochondrial decay and RNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alpha -lipoic acid. Proc Natl Acad Sci USA 2002 Feb 19;99(4):2356-61.
  48. Hagen TM, Liu J, Lykkesfeldt J, Wehr CM, Ingersoll RT, Vinarsky V, Bartholomew JC, Ames BN. Feeding acetyl-L-carnitine and lipoic acid to old rats significantly improves metabolic function while decreasing oxidative stress. Proc Natl Acad Sci USA 2002 Feb 19;99(4):1870-5
  49. Hofmann M, Mainka P, Tritschler H, Fuchs J, Zimmer G. Decrease of red cell membrane fluidity and -SH groups due to hyperglycemic conditions is counteracted by alpha-lipoic acid. Arch Biochem Biophys 1995 Dec 1;324(1):85-92.
  50. Haramaki N, Assadnazari H, Zimmer G, Schepkin V, Packer L. The influence of vitamin E and dihydrolipoic acid on cardiac energy and glutathione status under hypoxia-reoxygenation. Biochem Mol Biol Int 1995 Oct;37(3):591-7. 9.
  51. Zimmer G, Beikler TK, Schneider M, Ibel J, Tritschler H, Ulrich H. Dose/response curves of lipoic acid R-and S-forms in the working rat heart during reoxygenation: superiority of the R-enantiomer in enhancement of aortic flow. J Mol Cell Cardiol 1995 Sep;27(9):1895-903
  52. Haramaki N, Packer L, Assadnazari H, Zimmer G. Cardiac recovery during post-ischemic reperfusion is improved by combination of vitamin E with dihydrolipoic acid. Biochem Biophys Res Commun 1993 Nov 15;196(3):1101-7.
  53. Moini, H., Tirosh, O., R-Alpha Lipoic Acid Action on Cell Redox Status, the Insulin Receptor, and Glucose Uptake in 3T3-L1 Adipocytes; Archives of Biochem & BioPhys 397, No2 384-391 (2002)
  54. Liu, J. Killilea, D.W. et.al., Age-associated mitochondrial oxidative decay: Improvement of carnitine acetyltransferase substrate binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Nat Acad Sci 99, 1876-1881 (2002).
  55. Hager, K., Marahrens, A.,et.al. Alpha lipoic acid as a new treatment option for Alzheimer type dementia, Arch Geron Geriatr 32 (3): 275-282 (2001).
  56. Hermann, R.; Niebch, G.; Enantioselective pharmacokinetics and bioavailability of different racemic alpha lipoic acid formulations in healthy volunteers. Eur J Pharm Sci 4: 167-174 (1996).
  57. Craig J. McMackin et.al. Effect of Combined Treatment with Alpha Lipoic Acid and Acetyl-L-Carnitine on Vascular Function and Blood Pressure in Coronary Artery Disease Patients. J Clin Hypertens (Greenwich). Apr 2007; 9(4): 249–255.

 

Reviews

There are no reviews yet.

Be the first to review “ALA – ALC 60 capsules”

Related products